Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01239446
Other study ID # 0390-10-RMB_BRODOV
Secondary ID
Status Not yet recruiting
Phase N/A
First received November 10, 2010
Last updated November 10, 2010
Start date January 2011

Study information

Verified date November 2010
Source Rambam Health Care Campus
Contact Yafim Brodov, MD
Phone +972502061452
Email y_brodov@rambam.health.gov.il
Is FDA regulated No
Health authority Israel: Ethics CommissionIsrael: Ministry of Health
Study type Interventional

Clinical Trial Summary

Mediastinal irradiation for treatment of malignancy increases the risk for coronary artery disease (CAD), while diabetes mellitus or other known risk factors can be absent at the time of the first coronary event. Radiation-induced atherosclerosis affects the coronary ostia and proximal coronary segments, or causes diffuse microvascular damage. Younger patients and those exposed to high radiation doses (> 35 Gy) have a higher risk for developing premature CAD and likely may benefit from coronary assessment.

A novel hybrid imaging technique that combines SPECT and CTCA has been shown to overcome the individual pitfalls and the diagnostic challenges of stand-alone SPECT and CCTA, improve the lesion detectability and sensitivity in patients with balanced diffuse lesions as well as the specificity and mainly PPV of CTCA.

The aim of the study is to perform hybrid SPECT/CTCA in asymptomatic patients with HL who have received radiotherapy to the mediastinum in order to allow an early diagnosis of hemodynamically significant CAD that will need further therapeutic interventions.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date
Est. primary completion date January 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Asymptomatic HL patients without evidence of disease and without prior history of CAD that underwent mediastinal irradiation due to HL

Exclusion Criteria:

- Known CAD (these patients will be excluded from the imaging study, but will be analyzed as separate control group)

- active HL or other active malignancy

- chronic renal failure

- pregnant/ nursing women

- previous allergic reaction to iodine contrast media

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Other:
Not relevant (there is no intervention in the present study)
Not relevant (there is no intervention in the present study)

Locations

Country Name City State
Israel Rambam Healthcare Campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
Rambam Health Care Campus

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Extent of coronary artery plaques and number of perfusion defects in patients enrolled. 12 months No